February 6, 2020 / 10:26 PM / 11 days ago

BRIEF-Assertio Therapeutics Announces Sale Of Nucynta Franchise To Collegium Pharmaceutical For $375.0 Million

Feb 6 (Reuters) - Assertio Therapeutics Inc:

* ASSERTIO THERAPEUTICS ANNOUNCES SALE OF NUCYNTA® FRANCHISE TO COLLEGIUM PHARMACEUTICAL FOR $375.0 MILLION

* ASSERTIO THERAPEUTICS INC - COMPANY INTENDS TO USE CASH PROCEEDS TO RETIRE ITS OUTSTANDING DEBT

* ASSERTIO THERAPEUTICS INC - COLLEGIUM WILL PAY ASSERTIO $375.0 MILLION IN CASH AT CLOSING, LESS ROYALTIES PAID TO ASSERTIO IN 2020

* ASSERTIO THERAPEUTICS INC - COLLEGIUM WILL ALSO PAY ASSERTIO FOR CERTAIN INVENTORIES AND EQUIPMENT RELATING TO PRODUCTS

* ASSERTIO THERAPEUTICS INC - COMPANY IS ALSO ANNOUNCING THAT IT IS NO LONGER PURSUING DEVELOPMENT OF LONG-ACTING COSYNTROPIN Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below